4-(4-but-2-ynyloxyphenylsulfanyl)-4-hydroxycarbamoylpiperidine-1-carboxylic acid tert-butyl ester | 287200-81-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(4-but-2-ynyloxyphenylsulfanyl)-4-hydroxycarbamoylpiperidine-1-carboxylic acid tert-butyl ester
• 英文别名: 4-(4-but-2-ynyloxy-phenylsulfanyl)-4-hydroxycarbamoyl-piperidine-1-carboxylic acid tert-butyl ester；tert-butyl 4-(4-but-2-ynoxyphenyl)sulfanyl-4-(hydroxycarbamoyl)piperidine-1-carboxylate
• CAS: 287200-81-1
• 化学式: C₂₁H₂₈N₂O₅S
• 分子量: 420.53
• InChiKey: DNSZKZUFQIXHCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(4-but-2-ynyloxyphenylsulfanyl)-4-hydroxycarbamoylpiperidine-1-carboxylic acid tert-butyl ester 在 双氧水 作用下， 以 甲醇 、 水 为溶剂， 生成 Tert-butyl 4-{[4-(but-2-ynyloxy)phenyl]sulfinyl}-4-[(hydroxyamino)-carbonyl]piperidine-1-carboxalate
  参考文献：
  名称：

  ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS

  摘要：

  公开号：

  EP1147085B1
• 作为产物：
  描述：

  N-Boc-4-哌啶甲酸乙酯 在 sodium hydroxide 、 草酰氯 、 盐酸羟胺 、 叔丁基锂 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.17h， 生成 4-(4-but-2-ynyloxyphenylsulfanyl)-4-hydroxycarbamoylpiperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of 4-alkynyloxy Phenyl Sulfanyl, Sulfinyl, and Sulfonyl Alkyl Hydroxamates as Tumor Necrosis Factor-α Converting Enzyme and Matrix Metalloproteinase Inhibitors

  摘要：

  A series of 4-alkynyloxy phenyl sulfanyl, sulfinyl and sulfony alkyl and piperidine-4-carboxylic acid hydroxamides were synthesized. Their structure-activity relationships, against tumor necrosis factor-alpha (TACE) and matrix metalloproteinase (NIMP) inhibitor activities, are presented by investigating the oxidation state on sulfur and altering the P1' substituent. The sulfonyl derivatives 20-24 carrying a 4-butynyloxy moiety were selective TACE inhibitors over the MMPs tested. The sulfinyl derivatives showed a preference for a specific oxidation on sulfur as in compounds 25-28. The selectivity over MMPs was also demonstrated in the sulfonyl series. The enhanced cellular activity was achieved upon incorporating a butynyloxy substituent in the piperidene series. Compounds 64 and 65 were potent inhibitors of TNF-alpha release in the mouse at 100 mg/kg po.

  DOI：

  10.1021/jm040086x

文献信息

• Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors
  申请人：WYETH

  公开号：US20040229924A1

  公开（公告）日：2004-11-18

  Compounds of the formula: 1 useful in the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.

  该式的化合物：1在治疗关节炎、肿瘤转移、组织溃疡、异常伤口愈合、牙周病、骨病、糖尿病（胰岛素抵抗）和HIV感染方面有用。
• Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
  申请人：American Cyanamid Company

  公开号：US20020086890A1

  公开（公告）日：2002-07-04

  Compounds of the formula: 1 useful in the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.

  以下公式化合物：1，对于治疗关节炎、肿瘤转移、组织溃疡、异常伤口愈合、牙周疾病、骨疾病、糖尿病（胰岛素抵抗）和HIV感染非常有用。
• Method for the treatment of polycystic kidney disease
  申请人：——

  公开号：US20040063672A1

  公开（公告）日：2004-04-01

  The present invention provides a method for treating, inhibiting the progression of, or eradicating polycystic kidney disease of in a patient in need thereof which comprises providing to said patient an effective amount of a TACE inhibitor compound alone or in combination with an effective amount of an EDF receptor kinase inhibitor.

  本发明提供了一种治疗、抑制进展或根除多囊肾病的方法，该方法包括向需要该治疗的患者提供有效量的TACE抑制剂化合物，单独或与有效量的EDF受体激酶抑制剂化合物联合使用。
• US6358980B1
  申请人：——

  公开号：US6358980B1

  公开（公告）日：2002-03-19
• US6753337B2
  申请人：——

  公开号：US6753337B2

  公开（公告）日：2004-06-22